SG001 + doxorubicin hydrochloride liposome

SG001 + doxorubicin hydrochloride liposome is a **combination drug** consisting of **SG001** (details on SG001 itself are not provided in the sources) and **doxorubicin hydrochloride liposome**, a liposomal formulation of the anthracycline chemotherapy agent doxorubicin. Doxorubicin hydrochloride liposome works primarily as a topoisomerase II inhibitor, interfering with DNA replication and repair by blocking the topoisomerase II enzyme, thereby damaging DNA and impeding cancer cell growth[2][3][4][5]. Encapsulation in liposomes (specifically Stealth/PEGylated liposomes) helps the drug evade immune detection, circulates longer in plasma, and enables better tumor targeting by increasing accumulation in cancer tissue[1][3][5]. The primary indications for doxorubicin hydrochloride liposome (alone or in combination) are ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma, especially in patients who have failed previous therapies[1][2][4][5].

Brand names

DoxilLipodoxLipodox 50Lipodox50Lipodox-50

Other names

SG001 + doxorubicin hydrochloride liposomedoxorubicin liposomedoxorubicin HCl liposomedoxorubicin hydrochloride liposomal